Podcasts about frcpath

In this special edition, we take you inside the Infection Control African Network Congress 2025, held in beautiful Cape Town from 29 June to 2 July. Vin was on the ground capturing the energy, innovation, and passion driving infection prevention and control (IPC) across Africa and beyond. From cutting edge updates in infection control programs to inspiring discussions on IPC education, this episode is packed with insights straight from the experts. And for an extra twist, three conference attendees stepped up as momentary messengers for the day, bringing fresh perspectives as they interviewed some of the most fascinating voices at the congress.Our adhoc hosts:Dr Lesego MothibiDr Gilda MadeiraDr Julia PhambaneAbout our Guests: Professor Shaheen Mehtar MBBS, FRCPath, FCPath, MD, see bio HERE: An overview of the congressAnn Versporten, MEHS, MPH, Research scientist, University of Antwerp, see bio HERE: Co-ordinating the Global PPSAnnelies Boven, MSc, PhD candidate, University of Antwerp: Constructing the Operational module of the Global PPSBuyiswa Lizzie Sithole, IPC Consultant, see bio HERE: Challenges in implementing IPC practices in displaced and war-torn areas, and IPC strategies that work in the primary healthcare setting.Professor Joost Hopman, MD, PhD, DTMH see bio HERE: IPC and the hospital design and The effect of climate change on infectious diseaseReshma Misra, MSc, Assistant Director: Provincial Infection Prevention and Control – KwaZulu Natal, see her bio HERE: Antimicrobial prescribing and HAI surveillance in KZN, and Primary Health Care preparedness for a pandemic Resources from this episode:ICAN Website (https://icanetwork.co.za/)Global PPS website8 core components of IPCWE'D LOVE YOUR FEEDBACK ON THIS EPISODE – Visit the Microbe Mail website to sign up for updates Follow on:Instagram: Microbe_MailX/Twitter: @microbemailFacebook: MicrobeMailTiktok: @microbe.mailWatch this episode on our new YouTube channel: Microbe MailE-mail us:

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UMD865. CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE credit will be available until July 10, 2026.The Road Ahead for Enhanced Sequential Care in CLL—Updates With Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UMD865. CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE credit will be available until July 10, 2026.The Road Ahead for Enhanced Sequential Care in CLL—Updates With Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UMD865. CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE credit will be available until July 10, 2026.The Road Ahead for Enhanced Sequential Care in CLL—Updates With Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UMD865. CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE credit will be available until July 10, 2026.The Road Ahead for Enhanced Sequential Care in CLL—Updates With Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UMD865. CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE credit will be available until July 10, 2026.The Road Ahead for Enhanced Sequential Care in CLL—Updates With Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UMD865. CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE credit will be available until July 10, 2026.The Road Ahead for Enhanced Sequential Care in CLL—Updates With Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AZC865. CME credit will be available until 19 June 2026.Navigating the Layers of Complexity in R/R B-Cell Cancers: From Clinical Prognosis to Emerging Therapeutic Prospects in CLL/SLL, MCL, and DLBCL In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AZC865. CME credit will be available until 19 June 2026.Navigating the Layers of Complexity in R/R B-Cell Cancers: From Clinical Prognosis to Emerging Therapeutic Prospects in CLL/SLL, MCL, and DLBCL In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AZC865. CME credit will be available until 19 June 2026.Navigating the Layers of Complexity in R/R B-Cell Cancers: From Clinical Prognosis to Emerging Therapeutic Prospects in CLL/SLL, MCL, and DLBCL In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AZC865. CME credit will be available until 19 June 2026.Navigating the Layers of Complexity in R/R B-Cell Cancers: From Clinical Prognosis to Emerging Therapeutic Prospects in CLL/SLL, MCL, and DLBCL In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AZC865. CME credit will be available until 19 June 2026.Navigating the Layers of Complexity in R/R B-Cell Cancers: From Clinical Prognosis to Emerging Therapeutic Prospects in CLL/SLL, MCL, and DLBCL In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AZC865. CME credit will be available until 19 June 2026.Navigating the Layers of Complexity in R/R B-Cell Cancers: From Clinical Prognosis to Emerging Therapeutic Prospects in CLL/SLL, MCL, and DLBCL In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RFR865. CME credit will be available until March 27, 2026.Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RFR865. CME credit will be available until March 27, 2026.Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RFR865. CME credit will be available until March 27, 2026.Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RFR865. CME credit will be available until March 27, 2026.Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RFR865. CME credit will be available until March 27, 2026.Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RFR865. CME credit will be available until March 27, 2026.Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RFR865. CME credit will be available until March 27, 2026.Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RFR865. CME credit will be available until March 27, 2026.Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions

Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions

Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions

Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions

Ian SD Roberts, MBChB, FRCPath / Joris Roelofs, MD, PhD - Best Practices in Renal Pathology: Avoiding Common Pitfalls in the Diagnostic Pathways for Glomerular Diseases

Ian SD Roberts, MBChB, FRCPath / Joris Roelofs, MD, PhD - Best Practices in Renal Pathology: Avoiding Common Pitfalls in the Diagnostic Pathways for Glomerular Diseases

Ian SD Roberts, MBChB, FRCPath / Joris Roelofs, MD, PhD - Best Practices in Renal Pathology: Avoiding Common Pitfalls in the Diagnostic Pathways for Glomerular Diseases

Ian SD Roberts, MBChB, FRCPath / Joris Roelofs, MD, PhD - Best Practices in Renal Pathology: Avoiding Common Pitfalls in the Diagnostic Pathways for Glomerular Diseases

Stephen Jolles, MRCP, FRCPath, PhD - The Many Faces of Primary Immunodeficiencies: Exploring the Plethora of Possibilities Impacting Patient-Integrated Care

Stephen Jolles, MRCP, FRCPath, PhD - The Many Faces of Primary Immunodeficiencies: Exploring the Plethora of Possibilities Impacting Patient-Integrated Care

When you think about rural healthcare, you may not think about Scotland, but Scotland has some very rural areas that deal with similar issues we deal with in rural America.  Hear about what they are doing in rural Scotland to deliver health and wellbeing to their residents, by listening to our conversation with Dr. Emma Watson, 2021-22 U.K. Harkness Fellow in Health Care Policy and Practice Deputy Medical Director at NHS Highland. “NHS Highland delivers integrated health and social care, so it is not just about illness.” ~Dr. Emma Watson Dr. Emma Watson MSc, FRCPath, FRCPEd is a 2020-21 UK Harkness Fellow in Healthcare Policy and Practice.  A Consultant Medical Microbiologist by background and a senior clinical systems leader in Scotland, she is an expert in quality improvement and in medical education and workforce planning.  Emma is Deputy Medical Director in NHS Highland which is, geographically, one of the largest and most sparsely populated combined health and social care systems in the UK.  She is also a senior medical adviser in the Scottish Government.  In both roles her focus is on developing innovative approaches to ensuring equitable access to high quality health care services with a sustainable healthcare workforce, particularly in remote and rural areas.   Emma has led a number of major change programs including the development of Scotland's first graduate entry medical school.  Emma previously held a post in the Scottish Government as Clinical Lead for the Scottish Patient Safety Program during which time she ensured quality improvement methodology translated from the development of health policy and strategy through to implementation across the entirety of the Scottish healthcare system.  Scotland was the first country in the world to implement a patient safety program on a whole system basis at national level.  As Director of Medical Education in NHS Highland she focused on the delivery of high quality medical education as a tool to increase recruitment and attract young doctors to the region as well as ensuring there is now an established programme to encourage young people from the area to go to medical school.  During the COVID-19 pandemic she led the clinical response in her region and ensured there was a whole system approach to manage the impact of the virus.  

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YXF865. CME/MOC credit will be available until December 31, 2024.The ‘Clot' Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor TherapyPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novo Nordisk, Inc.DisclosuresAmy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Sanofi-Genzyme; and Takeda Pharmaceutical Company Limited.Speakers Bureau participant with CSL Behring; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Sanofi-Genzyme; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.Prof Pratima Chowdary, MD, FRCPATH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bayer Corporation; BioMarin/Boehringer Ingelheim Pharmaceuticals, Inc.; Centessa Pharmaceuticals plc/Johnson & Johnson Services, Inc.; CSL; Freeline; Novo Nordisk A/S; Pfizer; Sanofi; Swedish Orphan Biovitrum AB; and Takeda Pharmaceutical Company Limited/Chugai Pharmaceutical Co., Ltd.Grant/Research Support from Freeline; Novo Nordisk A/S; Pfizer; and Swedish Orphan Biovitrum AB.Speakers Bureau participant with BioMarin/Boehringer Ingelheim Pharmaceuticals, Inc.; Novo Nordisk A/S; Pfizer; Sanofi; Swedish Orphan Biovitrum AB; and Takeda Pharmaceutical Company Limited/Chugai Pharmaceutical Co., Ltd.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YXF865. CME/MOC credit will be available until December 31, 2024.The ‘Clot' Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor TherapyPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novo Nordisk, Inc.DisclosuresAmy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Sanofi-Genzyme; and Takeda Pharmaceutical Company Limited.Speakers Bureau participant with CSL Behring; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Sanofi-Genzyme; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.Prof Pratima Chowdary, MD, FRCPATH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bayer Corporation; BioMarin/Boehringer Ingelheim Pharmaceuticals, Inc.; Centessa Pharmaceuticals plc/Johnson & Johnson Services, Inc.; CSL; Freeline; Novo Nordisk A/S; Pfizer; Sanofi; Swedish Orphan Biovitrum AB; and Takeda Pharmaceutical Company Limited/Chugai Pharmaceutical Co., Ltd.Grant/Research Support from Freeline; Novo Nordisk A/S; Pfizer; and Swedish Orphan Biovitrum AB.Speakers Bureau participant with BioMarin/Boehringer Ingelheim Pharmaceuticals, Inc.; Novo Nordisk A/S; Pfizer; Sanofi; Swedish Orphan Biovitrum AB; and Takeda Pharmaceutical Company Limited/Chugai Pharmaceutical Co., Ltd.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YXF865. CME/MOC credit will be available until December 31, 2024.The ‘Clot' Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor TherapyPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novo Nordisk, Inc.DisclosuresAmy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Sanofi-Genzyme; and Takeda Pharmaceutical Company Limited.Speakers Bureau participant with CSL Behring; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Sanofi-Genzyme; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.Prof Pratima Chowdary, MD, FRCPATH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bayer Corporation; BioMarin/Boehringer Ingelheim Pharmaceuticals, Inc.; Centessa Pharmaceuticals plc/Johnson & Johnson Services, Inc.; CSL; Freeline; Novo Nordisk A/S; Pfizer; Sanofi; Swedish Orphan Biovitrum AB; and Takeda Pharmaceutical Company Limited/Chugai Pharmaceutical Co., Ltd.Grant/Research Support from Freeline; Novo Nordisk A/S; Pfizer; and Swedish Orphan Biovitrum AB.Speakers Bureau participant with BioMarin/Boehringer Ingelheim Pharmaceuticals, Inc.; Novo Nordisk A/S; Pfizer; Sanofi; Swedish Orphan Biovitrum AB; and Takeda Pharmaceutical Company Limited/Chugai Pharmaceutical Co., Ltd.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

In this Episode, Callum reflect on his recent runaway success passing the FRCPath Part 2, passes on some tips and tricks for the exam, and then we talk about what 3 antibiotics we would take with us to a Desert Island (that has all pathogens and environments where you would find said pathogens, so not just a desert apparently). 'Prepping to Pass' episodes mentioned: 40, 42, 43 & 50.The Table and Links mentioned in this episode can be found here: https://idiots.notion.site/70-Reflections-on-Part-2-2023-a193fd830c9b4d6c9381107471fcdbca Support the showQuestions, comments, suggestions to idiotspodcasting@gmail.com or on X/Threads @IDiots_podPrep notes for completed episodes can be found here (Not all episodes have prep notes).If you are enjoying the podcast please leave a review on your preferred podcast app!Feel like giving back? Donations of caffeine gratefully received!https://www.buymeacoffee.com/idiotspod

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

The cure for multiple myeloma only happens with patient participation in research. In this episode, Faith Davies, MBBCh, MRCP, MD, FRCPath of the NYU Langone will share how research works in multiple myeloma, the various stages in clinical trials, the most critical steps that move curative therapies forward, how barriers to a cure can be removed and how patient participation is essential to the entire process.  Thanks to our episode sponsor, GSK

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with a variety of specialists in neurology who presented research and gave talks at 4 recent major medical meetings—the Consortium of MS Centers Annual Meeting, the Annual Joint SLEEP Meeting, the Advanced Therapeutics in Movement and Related Disorders Congress, and the American Headache Society's Annual Scientific Meeting. Those included in this week's episode, in order of appearance, are: Amit Bar-Or, MD, FRCPC, FAAN, FANA, the Melissa and Paul Anderson President's Distinguished Professor at the Perelman School of Medicine of the University of Pennsylvania. Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, a professor of neurology at Barts and The London School of Medicine and Dentistry. Dayna Johnson, PhD, MPH, MSW, MS, a sleep epidemiologist and assistant professor at the Rollins School of Public Health at Emory University. John Winkelman, MD, PhD, the chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital. Laxman Bahroo, DO, a professor of neurology and the residency program director at MedStar Georgetown University Hospital. Ling Wan-Albert, OTD, OTR/L, an assistant professor of occupational therapy at the New York Institute of Technology. Sara Pavitt, MD, the chief of headache at UT Austin Dell Children's Hospital. Ali Ezzati, MD, the director of the Neuroinformatics Program at the University of California, Irvine. Want more from all of NeurologyLive's coverage of these medical meetings—including dozens more interviews with expert clinicians—click the links below: Consortium of Multiple Sclerosis Centers Annual Meeting SLEEP, the Joint American Academy of Sleep Medicine and the Sleep Research Society Meeting Advanced Therapeutics in Movement and Related Disorders Congress American Headache Society Annual Scientific Meeting Episode Breakdown: 1:15 – Bar-Or on the potential of BTK inhibition in multiple sclerosis at CMSC 2023 4:40 – Giovannoni on the understanding of MS as a smoldering disease at CMSC 2023 10:30 – Johnson on multilevel efforts to address modifiable factors of sleep health at SLEEP 2023 13:05 – Winkelman on moving away from dopamine agonists as first-line treatments for restless legs syndrome at SLEEP 2023 15:30 – Bahroo on the role of botulinumtoxins in Parkinson disease care at ATMRD 2023 19:00 – Wan-Albert on the impact of social isolation on cognition at ATMRD 2023 22:10 – Pavitt on the universal knowledge about pediatric headache for neurologists and nonspecialists at AHS 2023 24:05 – Ezzati on the use of machine learning models to improve treatment optimization in heterogenous migraine at AHS 2023 This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

In the latest episode of The HemOnc Pulse, Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil, a lymphoma specialist at Oxford Cancer and Haematology Centre, discusses the findings from the HoLISTIC Consortium, and what he thinks about checkpoint inhibitors upfront in the treatment of Hodgkin lymphoma.